Clinical trial
Open Label Extension Study of PREOS
NCT00172133 · Shire, Industry · Completed
Key facts
| NCT number | NCT00172133 |
|---|---|
| Title | Open Label Extension Study of PREOS |
| Official title | An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study) |
| Acronym | OLES |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | ALX1-11 (drug) |
| Enrollment | 1,683 |
| Start date | Oct 16, 2001 |
| Primary completion | Apr 13, 2005 |
| Completion | Apr 13, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | May 17, 2021 |
| Countries | Argentina, Brazil, Canada, Israel, Mexico, Romania, Russia, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: